Best Medicines for All
Give Hope, Provide Health, Share Happiness
Who we are
Viriom Inc. is a commercial and late-stage biotech company developing novel therapies and prophylactic medicines against HIV-1 and Hepatitis B Virus (HBV). Viriom's pipeline includes: Elpida® (elsulfavirine), the best-in-class NNRTI that obtained first market authorization in 2017; novel fixed doze combination single pill regimens; extended release weekly oral formulations; and long-acting injectable therapy and prophylaxis. Viriom is also developing a highly potent prodrug of the antiviral tenofovir to treat HIV-1 and Hepatitis B patients. Viriom combines its extended release and long-acting injectable compounds with partners’ therapies with curative potential.
Viriom is developing breakthrough medicines that are effective and affordable with the ultimate goal of curing HIV and chronic HBV infections in both developing and developed countries.
Viriom China has been named the only foreign finalist of the 2018 Zhongguancun International Frontier Science and Technology Innovation Competition. The Zhongguancun government offered Viriom China advantageous terms for research and manufacturing activities. It also supports Viriom’s regulatory and financing activities in China.
SAN DIEGO, Dec. 21, 2018 /PRNewswire/ -- Viriom, Inc. (San Diego, CA) announced today that it plans to report results from its Phase 1b clinical trial of once weekly dosing of oral elsulfavirine (Elida®, VM1500), a potent long acting nonnucleoside reverse transcriptase inhibitor (NNRTI) in HIV-uninfected volunteers in March 2019. This trial is designed to evaluate the safety and pharmacokinetics of elsulfavirine dosed once weekly for up to 8 weeks in up to 36 HIV-uninfected volunteers at a single clinical site in Moscow, Russia.
SAN DIEGO, Dec. 20, 2018 /PRNewswire/ -- Viriom, Inc. (San Diego, CA) announced today that it has initiated the first Phase 1 clinical trial of the long acting nanoformulation of VM1500A in HIV-uninfected volunteers. This trial is designed to evaluate the safety and pharmacokinetics of VM1500A once monthly dosing in up to 36 HIV-uninfected volunteers in a single site clinical trial in Moscow, Russia.
Ivan Solovyev presented Viriom’s plan on launching best in class HIV drugs in China – Elpida® – an effective, safe and well tolerated NNRTI with superior antiviral efficacy, resistance profile, pharmacokinetic properties, and VM1500A – a Long Acting Injectable Pre-Exposure Prophylaxis (PrEP).
Viriom's Elsulfavirine (Elpida™)-based regimens for treatment of HIV-1 infection will be available to all patients and physicians in both regionally and federally funded programs in Russia.
Viriom Inc. (Viriom) will present its innovative medicines for treatment and prophylaxis of HIV and announce the plan for accessing Chinese market at the international China BioMed Innovation and Investment Conference (CBIIC). The CBIIC will be held in Suzhou on September 18-20.
SAN DIEGO, April 16, 2018 /PRNewswire/ -- Viriom Inc. today announced that its study report "Elsulfavirine/VM1500A Long-Acting Parenteral and Oral Formulations for Treatment and Prevention of HIV-1 Infections" will be presented by Dr. Vadim Bichko, Viriom's Chief Scientific Officer, at the International Conference on HIV/AIDS, STDs & STIs on April 24th, 2018 in Valencia, Spain. The study evaluates new options for treatment and prevention of HIV/AIDS that would allow for infrequent dosing, thus facilitating patients' compliance and likely improving long-term treatment outcomes.
SAN DIEGO, CA, October 3d, 2017 -- Viriom Inc. announced today that it will be presenting “Preclinical Development of Elsulfavirine/VM1500A Long Acting Injectable Formulations" at the 16th European AIDS Conference in Milano, Italy. The study evaluates new options for treatment and prevention of AIDS, especially for patients with resistant HIV strains, that would allow for infrequent dosing, thus facilitating patients’ adherence and likely improving long-term treatment outcomes.
SAN DIEGO, Dec. 6, 2017 /PRNewswire/ -- Viriom Inc. is pleased to announce the appointment of Augustine Lawlor as Director of Viriom. Mr. Lawlor brings to Viriom his extensive operating experience in strategic business development, finance, management of mergers and acquisitions, as well as general management in the biotechnology industry. Mr. Lawlor is the Managing Partner of HealthCare Ventures LLC, where he has worked for over 17 years, and a board member of numerous life science companies. Before joining HealthCare Ventures, Mr. Lawlor served as Vice President of Corporate Development & Chief Financial Officer, and later as Chief Operating Officer, at LeukoSite, Inc.
SAN DIEGO, July 25, 2017 /PRNewswire/ -- Viriom, Inc (Viriom), a San Diego-based biotech company, today announced that on June 30, 2017 the Russian Ministry of Health (MoH) granted an approval to Viriom's non-nucleoside reverse transcriptase inhibitor (NNRTI) elsulfavirine (brand name Elpida®). Non-nucleoside reverse transcriptase inhibitors block HIV replication. The labeling requested was for the "treatment of HIV-1 infection in combination with other antiretroviral medicines.